Drug Trial Radar · NCT00262847
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Last checked: Nov 20, 2026Latest source record: Jul 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,873
Actual
Start
Sep 2005
Primary completion
Nov 2010
Study completion Apr 2015
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- Collaborators
- NRG Oncology
- First posted
- Dec 7, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized phase III trial studies carboplatin, paclitaxel, and bevacizumab to see how well they work compared to carboplatin, paclitaxel, and placebo in treating patients with stage III or stage IV ovarian epithelial, primary peritoneal, or fallopian tube cancer. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether carboplatin, paclitaxel, and bevacizumab are more effective than carboplatin, paclitaxel, and placebo in treating ovarian epithelial, primary peritoneal, or fallopian tube cancer.
Conditions
- Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Adenocarcinoma
- Fallopian Tube Mucinous Adenocarcinoma
- Fallopian Tube Serous Adenocarcinoma
- Fallopian Tube Transitional Cell Carcinoma
- Malignant Ovarian Mixed Epithelial Tumor
- Ovarian Brenner Tumor
- Ovarian Clear Cell Adenocarcinoma
- Ovarian Endometrioid Adenocarcinoma
- Ovarian Mucinous Adenocarcinoma
- Ovarian Serous Adenocarcinoma
- Ovarian Transitional Cell Carcinoma
- Primary Peritoneal Serous Adenocarcinoma
- Stage IIIA Fallopian Tube Cancer
- Stage IIIA Ovarian Cancer
- Stage IIIA Primary Peritoneal Cancer
- Stage IIIB Fallopian Tube Cancer
- Stage IIIB Ovarian Cancer
- Stage IIIB Primary Peritoneal Cancer
- Stage IIIC Fallopian Tube Cancer
- Stage IIIC Ovarian Cancer
- Stage IIIC Primary Peritoneal Cancer
- Stage IV Fallopian Tube Cancer
- Stage IV Ovarian Cancer
- Stage IV Primary Peritoneal Cancer
- Undifferentiated Fallopian Tube Carcinoma
- Undifferentiated Ovarian Carcinoma
Interventions
BevacizumabBiological
Given IV
CarboplatinDrug
Given IV
Laboratory Biomarker AnalysisOther
Correlative studies
PaclitaxelDrug
Given IV
PlaceboOther
Given IV
Quality-of-Life AssessmentOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free SurvivalTime frame: From study entry until first disease progression, death or date of last contact, up to 6 years
Locations
632 sites in 4 countries. Site status is shown where the registry gives one.
Northeast Alabama Regional Medical Center
Anniston, Alabama
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
Clearview Cancer Institute
Huntsville, Alabama
Mobile Infirmary Medical Center
Mobile, Alabama
Banner Thunderbird Medical Center
Glendale, Arizona
Banner Desert Medical Center
Mesa, Arizona
Banner Baywood Medical Center
Mesa, Arizona
Banner Good Samaritan Medical Center
Phoenix, Arizona
Western Regional CCOP
Phoenix, Arizona
Mayo Clinic in Arizona
Scottsdale, Arizona
Highlands Oncology Group PA - Fayetteville
Fayetteville, Arkansas
Washington Regional Medical Center - Fayetteville
Fayetteville, Arkansas
Mercy Hospital Fort Smith
Fort Smith, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California
East Bay Radiation Oncology Center
Castro Valley, California
Eden Hospital Medical Center
Castro Valley, California
Valley Medical Oncology Consultants-Castro Valley
Castro Valley, California
John Muir Medical Center-Concord Campus
Concord, California
Bay Area Breast Surgeons Inc
Emeryville, California
Northbay Cancer Center
Fairfield, California
Kaiser Permanente-Fremont
Fremont, California
Valley Medical Oncology Consultants-Fremont
Fremont, California
Cancer Care Associates of Fresno Medical Group Inc
Fresno, California
Saint Jude Medical Center
Fullerton, California
Loma Linda University Medical Center
Loma Linda, California
Long Beach Memorial Medical Center-Todd Cancer Institute
Long Beach, California
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California
Contra Costa Regional Medical Center
Martinez, California
El Camino Hospital
Mountain View, California
Highland General Hospital
Oakland, California
Alta Bates Summit Medical Center - Summit Campus
Oakland, California
Bay Area Tumor Institute
Oakland, California
Hematology and Oncology Associates-Oakland
Oakland, California
Tom K Lee Inc
Oakland, California
Kaiser Permanente-Oakland
Oakland, California
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California
Stanford Cancer Institute
Palo Alto, California
Showing 40 of 632 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.